4426-03-3

Basic information

• Product Name: CYCLOBUTYLACETONITRILE
• Synonyms: CYCLOBUTYLACETONITRILE;cyclobutylacetonitrile(SALTDATA: FREE);2-cyclobutylethanenitrile
• CAS NO: 4426-03-3
• Molecular Formula: C₆H₉N
• Molecular Weight: 95.14236
• Mol File: 4426-03-3.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 181.2°C at 760 mmHg
• Flash Point: 70.1°C
• Appearance: /
• Density: 0.933g/cm³
• Vapor Pressure: 0.86mmHg at 25°C
• Refractive Index: 1.455
• Storage Temp.: 2-8°C
• CAS DataBase Reference: CYCLOBUTYLACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOBUTYLACETONITRILE(4426-03-3)
• EPA Substance Registry System: CYCLOBUTYLACETONITRILE(4426-03-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 4426-03-3(Hazardous Substances Data)

Usage

General Description

CYCLOBUTYLACETONITRILE is a chemical compound with the molecular formula C6H9N. It is a colorless liquid that is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a solvent and intermediate in organic synthesis. CYCLOBUTYLACETONITRILE is known for its versatile properties, including its ability to undergo various chemical reactions such as halogenation, hydrolysis, and condensation. Its uses also extend to the production of perfumes and flavoring agents due to its aromatic properties. However, it should be handled with caution as it is considered toxic and may cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C6H9N/c7-5-4-6-2-1-3-6/h6H,1-4H2

Upstream product

• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 143-33-9 sodium cyanide 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 1191-95-3 cyclobutanone 
• 105-34-0 methyl 2-cyanoacetate 
• 773837-37-9 sodium cyanide 
• 13295-53-9 cyclobutylmethyl 4-methylbenzenesulfonate 
• 151-50-8 potassium cyanide 
• 5006-22-4 Cyclobutanecarbonyl chloride 
• 3779-29-1 diethyl cyclobutane-1,1-dicarboxylate 
• 4415-82-1 cyclobutanemethanol 
• 3721-95-7 Cyclobutanecarboxylic acid 

Downstream Products

• 6540-33-6 cyclobutylacetic acid 
• 6540-31-4 2-cyclobutylacetaldehyde 
• 885280-12-6 ethyl 4-cyclobutyl-3-oxobutanoate 
• 1433545-62-0 4-cyclobutyl-1-ethoxy-1,3-dioxobutan-2-yl 4-methoxybenzoate 
• 1433545-74-4 (2E)-3-amino-4-cyclobutyl-1-ethoxy-1-oxobut-2-en-2-yl 4-methoxybenzoate 
• 1433545-85-7 3-[(tert-butoxycarbonyl)amino]-4-cyclobutyl-1-ethoxy-1-oxobut-2-yl 4-methoxybenzoate 
• 394735-22-9 tert-butyl 4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-ylcarbamate 
• 1036931-36-8 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 394730-60-0 boceprevir 
• 91639-80-4 cyclobutyl-acetic acid anilide 
• 909717-49-3 (S)-2-Cyclobutyl-pent-4-enoic acid 3,5-bis-trifluoromethyl-benzylamide 
• 909717-47-1 (S)-4-Benzyl-3-((S)-2-cyclobutyl-pent-4-enoyl)-oxazolidin-2-one 
• 144164-36-3 (S)-4-Benzyl-3-(2-cyclobutyl-acetyl)-oxazolidin-2-one 

Relevant articles and documents

Rate constants and Arrhenius functions for ring opening of a cyclobutylcarbinyl radical clock and for hydrogen atom transfer from the Et 3B-MeOH complex

(Chemical Equation Presented) Kinetics of ring opening of the 1-cyclobutyldodecyl radical (1) were studied, and an Arrhenius function over the temperature range -20 to 47°C was determined. The radical clock reaction has kinetics described by log k = 13.2-13.5/2.313RT (in kcal/mol), and k = 1.5 × 103 s-1 at 20°C. Previous kinetic studies of hydrogen atom transfer trapping of radical 1 by the triethylborane-methanol complex at variable temperatures (J. Org. Chem. 2007, 72, 5098) were analyzed with the newly obtained kinetic data.

TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS

Compounds having activity as cancer agents are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salts, stereoisomers, tautomers, thereof, wherein R1, R2, R3 and L are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating a CDK7-dependent disease (e.g., cancer).

PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF

The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or lnterleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

THIAZOLES AS MODULATORS OF RORyt

The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and (A) are defined in the specification. The invention also comprises a co